Versant-built gene editing company Graphite speeds clinical plans with crossover-laden $150M series B 

Crossover investors have poured into Graphite’s $150 million series B round six months after the gene therapy company’s launch based on technology out of the Stanford lab of Matthew Porteus, setting it on a quick path to join its CRISPR-based gene editing peers on the public markets. 

“We’ve always been excited about how quickly this company could move, but there’s been staggering momentum since we put it together last year in terms of team building, execution and investor demand. The interest from crossover investors was substantial,” said Jerel Davis, managing director of founding investor Versant Ventures, which re-upped in the round...